■乳腺癌(BC)是全世界影响女性的所有类型癌症中广泛流行的恶性肿瘤。有重要证据表明,人乳头瘤病毒(HPV)感染可能会改变BC的致病性;然而,目前尚无确凿的数据。
■通过搜索五个数据库,包括EMBASE,IBECS,PubMed,Scopus,科学直接,谷歌学者,和WebofScience,我们对1990年至2022年6月30日的BC患者中HPV的患病率进行了全面的系统分析.在应用广泛的资格标准后,我们根据乳腺组织中HPV感染的患病率选择了74篇出版物进行进一步分析.所有数据都使用随机效应荟萃分析进行了分析,CochranQ检验和I2统计量用于通过亚组分析计算这些研究中患病率的异质性。通过亚组荟萃分析评估不同亚组中HPV患病率估计值的差异。
■总共,最初筛选了3156项研究,审查了93项全文研究,74符合纳入标准。在总共7156例BC活检中,HPV的总患病率为25.6%(95%CI=0.24-0.33,τ2=0.0369,估计值之间存在显著异质性(I2=97%,p<0.01).因此,进一步研究了45项具有可用对照的研究,在病例对照研究中,HPV的患病率为26.2%,总赔率为5.55(95%CI=3.67-8.41,I2=38%,τ2=1.4878,p<0.01)。HPV的进一步亚组分析显示HPV-16的最大患病率为9.6%(95%CI=3.06-11.86,I2=0%,τ2=0.6111,p<0.01)。在不同的地理区域中,欧洲报告了HPV的最高患病率,即,39.2%(95%CI=1.29-7.91,I2=18%,τ2=1.2911,p<0.01)。总体分布显示HPV-18是澳大利亚报道的常见HPV亚型。
目前的研究提供了BC患者中HPV流行的全球估计,并证明了该病毒与BC病因学之间的显着关联。然而,我们建议对潜在机制的进一步研究对于验证这一假设至关重要.
UNASSIGNED: Breast Cancer (BC) stands out as the widely prevalent malignancy among all the types of cancer affecting women worldwide. There is significant evidence that the pathogenicity of BC may be altered by Human Papillomavirus (HPV) infection; however, conclusive data are not yet available.
UNASSIGNED: By searching five databases, including EMBASE, IBECS, PubMed, Scopus, Science Direct, Google Scholar, and Web of Science, a thorough systematic analysis was conducted on the prevalence of HPV in BC patients from 1990 to June 30, 2022. After applying extensive eligibility criteria, we selected 74 publications for further analysis based on the prevalence of HPV infections in breast tissues. All of the data were analyzed using a random-effects meta-analysis, Cochran Q test and I2 statistic were used to calculate the heterogeneity of the prevalence among these studies using subgroup analysis. Variations in the HPV prevalence estimates in different subgroups were evaluated by subgroup meta-analysis.
UNASSIGNED: In total, 3156 studies were initially screened, resulting in 93 full-text studies reviewed, with 74 meeting inclusion criteria. Among a total of 7156 BC biopsies, the pool prevalence of HPV was 25.6% (95% CI= 0.24-0.33, τ2 = 0.0369 with significant heterogeneity between estimates (I 2 = 97% and p< 0.01). Consequently, 45 studies with available controls were further studied, and the prevalence of HPV in case-control studies was 26.2% with overall odds 5.55 (95% CI= 3.67-8.41, I 2 = 38%, τ2 = 1.4878, p< 0.01). Further subgroup analysis of HPV revealed HPV-16 had a maximum prevalence of 9.6% (95% CI= 3.06-11.86, I 2 = 0%, τ2 = 0.6111, p< 0.01). Among different geographical regions, Europe reported the maximum prevalence of HPV, i.e., 39.2% (95% CI=1.29-7.91, I 2 = 18%, τ2 = 1.2911, p< 0.01). Overall distribution showed HPV-18 was a frequent HPV subtype reported in Australia.
UNASSIGNED: Current study provides a global estimate of HPV prevalence in BC patients and demonstrates a significant association between this virus and BC etiology. Nevertheless, we recommend further investigation into the underlying mechanism is essential to validate this hypothesis.